Literature DB >> 12825826

Myelopathy from Waldenström's macroglobulinemia: improvement after Rituximab therapy.

Bernardo Liberato1, Adrienne Riethmuller, Raymond L Comenzo, Eric Lis, Jeffrey J Raizer.   

Abstract

Approximately 20% of patients with Waldenström's macroglobulinemia (WM) have neurological complications; primarily peripheral neuropathies and symptoms related to a hyperviscosity syndrome. We report a rare case of a patient presenting with a slowly progressive myelopathy due to WM who had a marked response to Rituximab therapy.

Entities:  

Mesh：

Substances：

Year:  2003        PMID： 12825826     DOI： 10.1023/a:1023912425610

Source DB:  PubMed          Journal:  J Neurooncol        ISSN： 0167-594X            Impact factor:   4.130


  9 in total

1.  Neurolymphomatosis in Waldenström's macroglobulinaemia.

Authors:  S Abad; A M Zagdanski; S Brechignac; B Thioliere; J C Brouet; X Mariette
Journal:  Br J Haematol       Date:  1999-07       Impact factor: 6.998

2.  Rituximab: active treatment of central nervous system involvement by non-Hodgkin's lymphoma?

Authors:  T W Ruhstaller; U Amsler; T Cerny
Journal:  Ann Oncol       Date:  2000-03       Impact factor: 32.976

Review 3.  Waldenström's macroglobulinemia: clinical features, complications, and management.

Authors:  M A Dimopoulos; P Panayiotidis; L A Moulopoulos; P Sfikakis; M Dalakas
Journal:  J Clin Oncol       Date:  2000-01       Impact factor: 44.544

4.  CD20-Directed Antibody-Mediated Immunotherapy Induces Responses and Facilitates Hematologic Recovery in Patients With Waldenstrom's Macroglobulinemia.

Authors:  Steven P. Treon; David B. Agus; Brian Link; Gilberto Rodrigues; Arturo Molina; Martha Q. Lacy; David C. Fisher; Christos Emmanouilides; Arthur I. Richards; Bruce Clark; Marjorie S. Lucas; Robert Schlossman; David Schenkein; Boris Lin; Eva Kimby; K. C. Anderson; John C. Byrd
Journal:  J Immunother (1991)       Date:  2001-05

5.  IgM antibody-related polyneuropathies: B-cell depletion chemotherapy using Rituximab.

Authors:  T D Levine; A Pestronk
Journal:  Neurology       Date:  1999-05-12       Impact factor: 9.910

6.  Treatable meningeal involvement in Waldenström's macroglobulinemia.

Authors:  J J Torrey; S B Katakkar
Journal:  Ann Intern Med       Date:  1984-09       Impact factor: 25.391

7.  Treatment of Waldenström's macroglobulinemia with rituximab.

Authors:  Meletios A Dimopoulos; Constantinos Zervas; Athanassios Zomas; Christos Kiamouris; Nora A Viniou; Vassiliki Grigoraki; Christos Karkantaris; Chrisanthi Mitsouli; Dimitra Gika; John Christakis; Nikolaos Anagnostopoulos
Journal:  J Clin Oncol       Date:  2002-05-01       Impact factor: 44.544

Review 8.  Radiation therapy and combination of cladribine, cyclophosphamide, and prednisone as treatment of Bing-Neel syndrome: Case report and review of the literature.

Authors:  Julio Delgado; Miguel Angel Canales; Beatriz Garcia; Javier Alvarez-Ferreira; Antonio Garcia-Grande; Fernando Hernandez-Navarro
Journal:  Am J Hematol       Date:  2002-02       Impact factor: 10.047

9.  [Myelopathy manifesting as macroglobulinemia].

Authors:  F Woimant; A Schanen; M A Bertail; M Dupuy; P Lecoz; M Haguenau; B Pépin
Journal:  Ann Med Interne (Paris)       Date:  1985
  9 in total
  1 in total

1.  [Leptomeningeal tumor cell infiltrations as a first manifestation of an immunocytoma (Waldenstrom's macroglobulinemia)].

Authors:  A Hug; J Haas; B Storch-Hagenlocher; B Wildemann
Journal:  Nervenarzt       Date:  2004-10       Impact factor: 1.214
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.